| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/06/2002 | EP1183534A2 Identification of novel mechanisms of drug resistance |
| 03/06/2002 | EP1183383A1 Siv-based packaging-deficient vectors |
| 03/06/2002 | EP1183376A1 Isoflavonoid methylation enzyme |
| 03/06/2002 | EP1183371A2 Composition designed for implementing an antitumoral or antiviral treatment in a mammal |
| 03/06/2002 | EP1183364A1 Groel muteins with improved stability |
| 03/06/2002 | EP1183344A2 Adam polynucleotides and polypeptides |
| 03/06/2002 | EP1183259A2 Azepinoindole derivatives, the production and use thereof |
| 03/06/2002 | EP1183258A1 Imidazo-containing heterocyclic compounds, their compositions and uses |
| 03/06/2002 | EP1183257A1 Triazolopyrimidinol compounds and salts thereof |
| 03/06/2002 | EP1183256A1 Purine derivatives, preparation method and pharmaceutical compositions containing same |
| 03/06/2002 | EP1183254A1 Substituted bicyclic heteroaryl compounds as integrin antagonists |
| 03/06/2002 | EP1183253A1 C7 ester substituted taxanes as antitumor agents |
| 03/06/2002 | EP1183252A1 New pharmaceutically active compounds |
| 03/06/2002 | EP1183251A1 Indolylpiperidine derivatives as antihistaminic and antiallergic agents |
| 03/06/2002 | EP1183250A1 Semi-synthesis of paclitaxel using dialkyldichlorosilanes |
| 03/06/2002 | EP1183245A1 Selective npy (y5) antagonists |
| 03/06/2002 | EP1183243A1 Short-acting benzodiazepines |
| 03/06/2002 | EP1183241A1 Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them |
| 03/06/2002 | EP1183240A1 Beta2-adrenoceptor agonists |
| 03/06/2002 | EP1183239A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
| 03/06/2002 | EP1183237A1 Novel antioxidants, preparation methods and uses |
| 03/06/2002 | EP1183236A1 Cinnamoylaminoalkyl-substituted benzenesulfonamide derivatives |
| 03/06/2002 | EP1183235A2 INHIBITORS OF FACTOR Xa |
| 03/06/2002 | EP1183234A1 INHIBITORS OF FACTOR Xa |
| 03/06/2002 | EP1183233A2 Bradykinin receptor antagonists |
| 03/06/2002 | EP1183232A2 Monofluoroalkyl derivatives |
| 03/06/2002 | EP1183231A1 Cytofectin dimers and methods of use thereof |
| 03/06/2002 | EP1183229A1 Glucagon antagonists/inverse agonists |
| 03/06/2002 | EP1183228A2 Esters of l-carnitine or alkanoyl l-carnitines |
| 03/06/2002 | EP1183074A1 Substituted biaryl ether compounds |
| 03/06/2002 | EP1183073A2 Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors |
| 03/06/2002 | EP1183050A2 Method for producing an injectable medicament preparation |
| 03/06/2002 | EP1183046A1 Aminotetralin derivative for the therapy of cardiovascular diseases |
| 03/06/2002 | EP1183043A2 Medicament for localised application, containing fibrinogen, thrombin, transglutaminases and proteinase inhibitors |
| 03/06/2002 | EP1183038A1 Plant preparation containing phenethylisothiocyanate |
| 03/06/2002 | EP1183037A2 Methods and compositions for modulating immune response and for the treatment of inflammatory disease |
| 03/06/2002 | EP1183034A1 Modulators of methylation for control of bacterial virulence |
| 03/06/2002 | EP1183033A1 Pyrrolotriazine inhibitors of kinases |
| 03/06/2002 | EP1183032A1 Method of enhancing insulin action |
| 03/06/2002 | EP1183031A1 Quinoxaline containing medicaments for post exposure prophylaxis of an hiv infection |
| 03/06/2002 | EP1183030A1 Methods of making and using n-desmethylzopiclone |
| 03/06/2002 | EP1183029A2 Pharmaceutical preparation containing the active substance diamorphine and its utilization in a method for treating opiate addiction |
| 03/06/2002 | EP1183028A2 New use of macrolide compounds for inducing chondrogenic differentiation |
| 03/06/2002 | EP1183027A1 Pharmaceutical formulations and methods comprising intranasal morphine |
| 03/06/2002 | EP1183026A2 Improved pharmaceutical formulations |
| 03/06/2002 | EP1183025A2 Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders |
| 03/06/2002 | EP1183024A1 Therapeutic use of melatonin |
| 03/06/2002 | EP1183023A1 Use of verapamil and verapamil derivatives for producing medicaments with an inhibiting effect on beta-glucuronidase in human tissue |
| 03/06/2002 | EP1183022A1 Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response |
| 03/06/2002 | EP1183021A1 Stimulating transport of glucose into animal tissue by the administration of pinitol |
| 03/06/2002 | EP1183020A2 Use of(-)(3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia |
| 03/06/2002 | EP1183019A2 Ace-2 inhibiting compounds and methods of use thereof |
| 03/06/2002 | EP1183017A1 Novel formulations comprising lipid-regulating agents |
| 03/06/2002 | EP1183015A1 Multilayered tablet for administration of a fixed combination of tramadol and diclofenac |
| 03/06/2002 | EP1183014A1 Controlled release and taste masking oral pharmaceutical compositions |
| 03/06/2002 | EP1183013A2 Melt granulation |
| 03/06/2002 | EP1183012A1 Novel formulations comprising lipid-regulating agents |
| 03/06/2002 | EP1183011A1 Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto |
| 03/06/2002 | EP1183010A2 Implantable gel compositions and method of manufacture |
| 03/06/2002 | EP1183009A1 Acidic buffered nasal spray |
| 03/06/2002 | EP1182939A1 The combined use of triglycerides containing medium chain fatty acids and exogenous lipolytic enzymes as feed supplements |
| 03/06/2002 | EP1182931A1 Stable biocidal compositions |
| 03/06/2002 | EP1182929A1 Osteonectin based toxic gene therapy for the treatment of calcified tumors and tissues |
| 03/06/2002 | EP1182927A1 Antimicrobial sanitizing lotion with skin protection properties |
| 03/06/2002 | EP1096944B1 Extracts of zanthoxylum bungeanum, pharmaceutical and cosmetic formulations containing them |
| 03/06/2002 | EP1032378B1 Use of a mixture of a diol and an alpha-hydroxy acid for the treatment of hyperkeratotic skin diseases |
| 03/06/2002 | EP0994865B1 Triazole compounds and the use thereof as dopamine-d 3-ligands |
| 03/06/2002 | EP0946548B1 Novel heterocyclic substituted pyrrolidine amide derivatives |
| 03/06/2002 | EP0942743B1 Topical preparation for introducing peptidaceous pharmacons in living organisms |
| 03/06/2002 | EP0938505B1 Anti-endoglin monoclonal antibodies and their use in anti-angiogenesis therapy |
| 03/06/2002 | EP0937043B1 Novel substituted tetrahydropyridin derivatives, method of preparation and pharmaceutical compositions containing them |
| 03/06/2002 | EP0912186B1 Progestogen-anti-progestogen regimens |
| 03/06/2002 | EP0906907B1 Compounds potentiating retinoid |
| 03/06/2002 | EP0896529B1 Estradiol and progesterone-based medicament |
| 03/06/2002 | EP0883403A4 Method for treating sexual dysfunctions |
| 03/06/2002 | EP0876372B1 Heteroarylcarboxamide derivatives |
| 03/06/2002 | EP0874845B1 Pyrido (2,3-b) pyrazine derivatives |
| 03/06/2002 | EP0848757B1 The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells |
| 03/06/2002 | EP0843681B1 Heterocycle-fused thiazole derivatives |
| 03/06/2002 | EP0835105B1 Pharmaceutical amiodarone composition for parenteral delivery |
| 03/06/2002 | EP0825854B1 Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| 03/06/2002 | EP0819122B1 1,3-dihydro-1-(phenylalkyl)-2h-imidazol-2-one derivatives having pdeiv and cytokine activity |
| 03/06/2002 | EP0760818B1 Use of tetrahydropteridine derivatives as no-synthase inhibitors |
| 03/06/2002 | EP0756595B1 Substituted 1,3-oxathiolanes with antiviral properties |
| 03/06/2002 | EP0754045B1 compositions comprising halofantrine in a special form |
| 03/06/2002 | EP0743945B1 Heterocyclic compounds and their preparation and use |
| 03/06/2002 | EP0740657B1 4-arylisoindole analgesics |
| 03/06/2002 | EP0734257B1 Pharmaceutical compositions for topical use containing (s)-2-(4-isobutylphenyl)propionic acid |
| 03/06/2002 | EP0710110B1 Antibodies of ring opened rapamycins |
| 03/06/2002 | EP0613371B1 New combination of formoterol and budesonide |
| 03/06/2002 | CN1339037A Pyrrolobenzodiazepine carboxyamide vasporessin agonists |
| 03/06/2002 | CN1339036A Thienylbenzoylbenzapines as vasporessin agonists |
| 03/06/2002 | CN1339035A Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists |
| 03/06/2002 | CN1339034A Potassium salt of (I(S))-omeprazole |
| 03/06/2002 | CN1339032A Reverse hydroxamate inhibitors of matrix metalloproteinases |
| 03/06/2002 | CN1339028A Pyrimidine-2,4,6-triones as inhibitors of matrix metalloproteinases |
| 03/06/2002 | CN1339027A New process for preparing pesticidal intermediates |
| 03/06/2002 | CN1339025A Indole derivatives and their use as MCP-1 antagonists |
| 03/06/2002 | CN1338958A The use of 4-H-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation |
| 03/06/2002 | CN1338946A Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications |